- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Allergan set to unveil eyelash-growing product
Irvine, Calif. - Allergan is planning to file a New Drug Application to the FDA by end of the third quarter of 2008 for bimatoprost, a synthetic prostaglandin analog, as a treatment to stimulate eyelash growth, according to a press release.
Irvine, Calif.
- Allergan is planning to file a New Drug Application to the FDA by end of the third quarter of 2008 for bimatoprost, a synthetic prostaglandin analog, as a treatment to stimulate eyelash growth, according to a press release.
Allergan has completed a clinical trial, demonstrating that bimatoprost, the active ingredient in Allergan's glaucoma drug, Lumigan. The product will likely be launched next summer, pending the FDA approval of the application.
In November, Allergan sued a a number of cosmetic companies selling "eyelash conditioners" for infringing on a patent covering both bimatoprost and related compounds called prostaglandins, according to the Wall Street Journal.
The company expects the product will exceed $500 million in global sales.
